A Missouri judge has approved Bayer’s proposed $7.25 billion settlement of lawsuits alleging that its Roundup weedkiller caused cancer, marking a significant development in litigation that has weighed on the German company’s finances for years. The settlement is intended to resolve nearly all current and future US claims covered by the agreement, although some cases remain outside the arrangement. Bayer has denied that Roundup causes cancer and maintains that scientific studies support the safety of glyphosate when used as directed. Reuters reported the court approval.

Bayer is facing approximately 65,000 claims in US state and federal courts from people who say they developed non-Hodgkin lymphoma after using the product at home or at work. Under the proposed settlement, eligible claimants could receive payments ranging from $10,000 to $165,000, depending on factors including diagnosis, age and exposure history. The settlement was announced in February and follows years of litigation after Bayer acquired Monsanto in 2018. The Reuters report details the claims and proposed payment ranges.

The approval could reduce uncertainty for Bayer and investors, but it does not mean every Roundup-related case has ended. Some plaintiffs oppose the settlement, arguing that the compensation is insufficient or that the arrangement could restrict future legal options. Bayer says the agreement provides a path to resolving a substantial portion of the litigation burden. The company will still face scrutiny over remaining cases, legal costs and the long-term financial impact of the settlement. Reuters continues to cover the company’s legal and financial exposure.

Related HeadlinesXtra Coverage

For further context, read Niron Magnetics’ planned US advanced-manufacturing investment.